Hostname: page-component-7479d7b7d-rvbq7 Total loading time: 0 Render date: 2024-07-11T05:25:50.612Z Has data issue: false hasContentIssue false
  • English
  • Français

The treatment of cognitive impairment in late-life depression: neurobiological predictors of treatment response

Published online by Cambridge University Press:  10 March 2021

Gwenn S. Smith
Gwenn S. Smith*
Affiliation:
Division of Geriatric Psychiatry and Neuopsychiatry, Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MarylandUSA21287
*
Email: gsmith95@jhmi.edu
Get access Rights & Permissions [Opens in a new window]

Abstract

An abstract is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Commentary
Information
International Psychogeriatrics , Volume 33 , Special Issue 2: Issue Theme: Schizophrenia and Depression in Older Adults , February 2021 , pp. 113 - 114
Copyright
© International Psychogeriatric Association 2021

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Bhalla, R. K. etal. (2009) Patterns of mild cognitive impairment after treatment of depression in the elderly. American Journal of Geriatric Psychiatry, 17, 308–316.CrossRefGoogle ScholarPubMed
Butters, M. A. etal. (2008) Imaging Alzheimer pathology in late-life depression with PET and Pittsburgh Compound-B. Alzheimer Disease and Associated Disorders, 22, 261–268.CrossRefGoogle ScholarPubMed
Colom-Cadena, M. etal. (2020) Synaptic Health Endpoints Working Group. The clinical promise of biomarkers of synapse damage or loss in Alzheimer’s disease. Alzheimer’s Research and Therapeutics, 2, 12, 21 CrossRefGoogle Scholar
Devi, L. and Ohno, M. (2016) Cognitive benefits of memantine in Alzheimer’s 5XFAD model mice decline during advanced disease stages. Pharmacology Biochemistry Behavior, 144, 60–68.CrossRefGoogle ScholarPubMed
Diniz, B. S., Butters, M. A., Albert, S. M., Dew, M. A. and Reynolds, C. F. 3rd. (2013) Late-life depression and risk of vascular dementia and Alzheimer’s disease: systematic review and meta-analysis of community-based cohort studies. British Journal of Psychiatry, 202, 329–335 CrossRefGoogle ScholarPubMed
Hirao, K. and Smith, G. S. (2014) Positron emission tomography molecular imaging in late-life depression. Journal of Geriatric Psychiatry and Neurology, 27, 13–23.CrossRefGoogle ScholarPubMed
Koenig, A. M. etal. (2015). Neuropsychological functioning in the acute and remitted States of late-life depression. Journal of Alzheimer’s Disease, 45, 175–185.CrossRefGoogle ScholarPubMed
Krause-Sorio, B. etal. (2020) [18F]FDDNP PET binding predicts change in executive function in a pilot clinical trial of geriatric depression. International Psychogeriatrics, 1–8.CrossRefGoogle Scholar
Lavretsky, H. etal. (2020) A Randomized Double-Blind Placebo-Controlled Trial of Combined Escitalopram and Memantine for Older Adults With Major Depression and Subjective Memory Complaints. American Journal of Geriatric Psychiatry, 28, 178–190.CrossRefGoogle ScholarPubMed
Manning, K. J. and Steffens, D. C. (2018) State of the science of neural systems in late-life depression: impact on clinical presentation and treatment outcome. Journal of the American Geriatric Society, 66, S17–S23 CrossRefGoogle ScholarPubMed
Mathias, L. K., Monette, P. J., Harper, D. G. and Forester, B. P. (2017) Application of magnetic resonance spectroscopy in geriatric mood disorders. International Review of Psychiatry, 29, 597–617 CrossRefGoogle ScholarPubMed
Pelton, G. H., Harper, O. L., Roose, S. P., Marder, K., D’Antonio, K. and Devanand, D. P. (2016) Combined treatment with memantine/es-citalopram for older depressed patients with cognitive impairment: a pilot study. International Journal of Geriatric Psychiatry, 31(6), 648–655.CrossRefGoogle ScholarPubMed
Rogawski, M. A. and Wenk, G. L. (2003) The neuropharmacological basis for the use of memantine in the treatment of Alzheimer’s disease. CNS Drug Reviews, 9, 275–308.CrossRefGoogle ScholarPubMed
Sweet, R. A. etal. (2004) Neuropathologic correlates of late-onset major depression. Neuropsychopharmacology, 29, 2242–2250.CrossRefGoogle ScholarPubMed
Villemagne, V. L., Doré, V., Burnham, S. C., Masters, C. L. and Rowe, C. C. (2018) Imaging tau and amyloid-β proteinopathies in Alzheimer disease and other conditions. Nature Review Neurology, 14, 225–236 CrossRefGoogle ScholarPubMed
Zhou, T., Wang, J., Xin, C., Kong, L. and Wang, C. (2019) Effect of memantine combined with citalopram on cognition of BPSD and moderate Alzheimer’s disease: a clinical trial. Experimental Therapeutics in Medicine, 17, 1625–1630.Google ScholarPubMed